Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)
China · Delayed Price · Currency is CNY 25.20
-0.30 (-1.18%)
Sep 10, 2026, 3:00 PM CST
SHA:603351 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,454 | 3,524 | 3,326 | 3,572 | 2,930 | 5,118 | |
Market Cap Growth | -12.07% | 5.95% | -6.86% | 21.88% | -42.75% | 71.80% |
Enterprise Value | 3,664 | 3,772 | 3,601 | 3,949 | 3,260 | 5,210 |
Last Close Price | 25.50 | 25.42 | 23.66 | 25.05 | 20.32 | 36.31 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.37 | 23.34 | 22.72 | 31.83 | 30.84 | 50.49 |
PS Ratio | 2.47 | 2.64 | 2.57 | 3.09 | 2.64 | 4.91 |
PB Ratio | 1.92 | 1.96 | 1.95 | 2.24 | 1.98 | 3.69 |
P/TBV Ratio | 2.07 | 2.09 | 2.09 | 2.40 | 2.11 | 3.92 |
P/FCF Ratio | 16.62 | 18.94 | 19.53 | 75.71 | - | - |
P/OCF Ratio | 13.39 | 14.79 | 15.00 | 29.70 | 26.89 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.62 | 2.83 | 2.78 | 3.42 | 2.94 | 5.00 |
EV/EBITDA Ratio | 11.65 | 12.59 | 13.02 | 19.72 | 18.05 | 32.14 |
EV/EBIT Ratio | 19.95 | 21.33 | 21.27 | 29.88 | 27.86 | 42.55 |
EV/FCF Ratio | 17.63 | 20.27 | 21.14 | 83.72 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.32 | 0.28 | 0.31 | 0.29 | 0.14 |
Debt / EBITDA Ratio | 1.31 | 1.86 | 1.69 | 2.39 | 2.26 | 1.21 |
Debt / FCF Ratio | 1.98 | 3.09 | 2.83 | 10.32 | - | - |
Net Debt / Equity Ratio | 0.11 | 0.08 | 0.14 | 0.21 | 0.22 | 0.08 |
Net Debt / EBITDA Ratio | 0.66 | 0.50 | 0.85 | 1.64 | 1.80 | 0.66 |
Net Debt / FCF Ratio | 0.96 | 0.81 | 1.37 | 6.96 | -2.60 | -0.43 |
Asset Turnover | 0.57 | 0.54 | 0.56 | 0.52 | 0.56 | 0.60 |
Inventory Turnover | 4.75 | 4.71 | 5.04 | 5.02 | 5.27 | 5.92 |
Quick Ratio | 0.84 | 0.97 | 0.82 | 0.72 | 0.48 | 0.71 |
Current Ratio | 1.27 | 1.30 | 1.20 | 1.08 | 0.81 | 1.10 |
Return on Equity (ROE) | 8.70% | 8.49% | 8.80% | 7.10% | 6.59% | 7.46% |
Return on Assets (ROA) | 4.64% | 4.45% | 4.54% | 3.74% | 3.68% | 4.40% |
Return on Invested Capital (ROIC) | 7.97% | 7.84% | 7.39% | 6.37% | 5.93% | 7.83% |
Return on Capital Employed (ROCE) | 9.90% | 9.30% | 9.50% | 7.70% | 7.50% | 8.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.49% | 4.28% | 4.40% | 3.14% | 3.24% | 1.98% |
FCF Yield | 6.02% | 5.28% | 5.12% | 1.32% | -4.26% | -4.83% |
Dividend Yield | 2.34% | 2.36% | 1.69% | 1.20% | 1.38% | 0.83% |
Payout Ratio | 59.50% | 42.98% | 37.88% | 47.61% | 56.70% | 44.64% |
Buyback Yield / Dilution | -0.78% | -0.32% | -0.29% | -1.00% | -0.35% | -2.25% |
Total Shareholder Return | 1.56% | 2.04% | 1.40% | 0.20% | 1.03% | -1.42% |